| INTRODUCTION
PcG genes were first identified for their role in regulating the expression of homeotic genes, which control the body plan of embryos along the longitudinal axis and segmentation in Drosophila. 1 PcG proteins form PRC in the nucleus. PRC are classified into PRC1 and PRC2 according to their biological characteristics. The core subunits of the mammalian PRC2 complex include EZH1/2, SUZ12, RbAp46/48, and EED. EZH1/2, which are histone methyltransferases, trimethylate histone H3 at lysine 27 (H3K27).
2,3 SUZ12 and EED activate methyltransferases and recruit PRC2 to the nucleosome, respectively. 4, 5 The histone modification H3K27me3 represses target genes and mediates the recruitment of PRC1 to the nucleosome by serving as a docking site for the PRC1 component CBX ( Figure 1A ). PRC1 functions in transcriptional repression by catalyzing the monoubiquitination of histone H2A at lysine 119 (H2AK119).
H2A ubiquitination blocks RNA polymerase II-mediated transcriptional elongation. 6 In addition, PRC1 induces chromatin independently of PRC2 ( Figure 1B) . [10] [11] [12] H2AK119ub1 recruits PRC2
to target genes and induces H3K27 trimethylation. 13, 14 Canonical and non-canonical PRC1 complexes have similar activity in the ubiquitination of H2A in a PRC2-dependent or -independent method, resulting in the maintenance of gene silencing. Association of EZH2, a methyltransferase of H3K27, with carcinogenesis has been studied in PcG genes. 27 High expression of EZH2 is associated with tumor aggressiveness in several cancers (Table 1) . 28 In hematological malignancies, EZH2 is overexpressed in AML, multiple myeloma (MM), and B-and T-cell lymphomas. High expression of EZH2 in MM is associated with poor patient outcomes and high-risk disease features, and pharmacological inhibition of EZH2 has anticancer effects in MM cell lines. 33, 34 In contrast, monoallelic gain-of-function mutations in tyrosine residue 641 of the SET domain in EZH2 are reported in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). 35 Mutations in alanine residue 677 are also observed in DLBCL. 36 These gain-of-function mutations result in a higher efficiency of mono-to di-and di-to tri-methylation than that of the wild-type enzyme. 37 Furthermore, EZH2 gain-of-function mutations contribute to the widespread redistribution of H3K27me3, inducing not only persistent transcriptional repression but also increased transcription at many loci. 53 These results suggest that activation of EZH2 contributes to malignant transformation and that EZH2 plays an oncogenic role in many malignant tumors. 
| ROLES OF EZH1/2 IN HSC
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| ROLE OF EZH1 IN HEMATOLOGICAL MALIGNANCIE S AND TARGETING THERAPY AGAINST EZH1/2
Enhancer of zeste homolog 2 plays an oncogenic role, especially in lymphoma and AML. A transgenic mouse model with a combination of Myc and EZH2 Y641F showed accelerated lymphoma development. 57 EZH2 deletion inhibits tumor progression concomitant with the induction of differentiation programs in mixed lineage leukemia (MLL)-AF9 fusion AML mice, suggesting that EZH2 is important for leukemogenesis. 58, 59 These studies identify EZH2 as a potential therapeutic target, and several EZH2 inhibitors, which are highly selective for the methyltransferase activity of EZH2, have been developed to target the oncogenic function of EZH2 ( 67 This indicates that leukemia stem cells (LSC), which are responsible for drug resistance and relapse of AML, are dependent not only on EZH2, as remaining EZH1 activity is sufficient for the self-renewal activity of LSC, despite the fact that EZH1 only partially compensates for the loss of EZH2. 74, 75 Work from our group showed that quiescent LSC express the highest levels of Ezh1/2, and dual inactivation of Ezh1/2 eradicates quiescent LSC to cure AML in experiments comparing Ezh1/2 dKO with Ezh2 sKO mice. 70 Furthermore, quiescent LSC are associated with PRC2-mediated suppression of Cyclin D, and dual inactivation of Ezh1/2 induces cell cycle progression and differentiation in quiescent LSC (Figure 2) . A novel EZH1/2 dual inhibitor, OR-S1 is an orally bioavailable small molecule compound that inhibits the histone methyltransferase activity of both EZH1 and EZH2 strongly and selectively. 71 OR-S1 reduces the number of LSC, suppresses leukemia progression, and prolongs survival without serious sideeffects. 70, 71 This drug, which induces differentiation and eradicates quiescent LSC, shows a synergistic effect on LSC with conventional chemotherapy agents, similar to the effect of all-trans-retinoic acid in acute promyelocytic leukemia. Thus, dual inhibition of EZH1/2 with an EZH1/2 dual inhibitor is effective for disrupting PRC2.
Indeed, OR-S1 suppresses H3K27me3 more potently in cells than UNC1999 and other EZH2 inhibitors. 71 This drug is more effective trial show that DS-3201b (a derivative of OR-S1) has early clinical activity and indicates the potential of this drug as a novel therapeutic option for patients with B-cell and T-cell lymphoma. 76 Further investigation in AML, ALL, and NHL is currently being pursued. AML, acute myeloid leukemia; ATL, adult T-cell leukemia/lymphoma; B-NHL, B-cell non-Hodgkin lymphomas; DLBCL, diffuse large B-cell lymphoma; ETP-ALL, early T-cell precursor acute lymphoblastic leukemia; EZH2, enhancer of zeste homolog 2; FL, follicular lymphoma; MDS, myelodysplastic syndrome; MDS/MPN, myelodysplastic syndrome/ myeloproliferative neoplasm; MF, myelofibrosis; MM, multiple myeloma; T-ALL, T-cell acute lymphoblastic leukemia.
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| DRUG RESISTANCE AND COMBINATION THERAPIES
Cancer cells can escape the effect of drugs, and drug resistance has been reported for EZH2 inhibitors and other drugs. 26 In an EZH2-mutated lymphoma cell line model, the acquisition of resistance was related to secondary mutations (Y111L and Y661D) in both wild-type and gain-of-function Y641N EZH2 alleles. 77 is an effective treatment against various diseases, and these results will be of value for the development of epigenetic therapies.
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